DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY

The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabig...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: N. A. Novikova (Údar), A. N. Volovchenko (Údar), D. A. Parfenov (Údar)
Formáid: LEABHAR
Foilsithe / Cruthaithe: «REMEDIUM GROUP» Ltd., 2019-06-01T00:00:00Z.
Ábhair:
Rochtain ar líne:Connect to this object online.
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Ar líne

Connect to this object online.

3rd Floor Main Library

Sonraí sealbhúcháin ó 3rd Floor Main Library
Gairmuimhir: A1234.567
Cóip 1 Ar fáil